DBV Technologies

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch DBVT and buy or sell other stocks, ETFs, and their options commission-free!

About DBVT

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. 

CEO
Daniel Tassé
CEODaniel Tassé
Employees
109
Employees109
Headquarters
Chatillon, Hauts-de-France
HeadquartersChatillon, Hauts-de-France
Founded
2002
Founded2002
Employees
109
Employees109

DBVT Key Statistics

Market cap
1.27B
Market cap1.27B
Price-Earnings ratio
-4.35
Price-Earnings ratio-4.35
Dividend yield
Dividend yield
Average volume
164.30K
Average volume164.30K
High today
$23.08
High today$23.08
Low today
$22.73
Low today$22.73
Open price
$21.96
Open price$21.96
Volume
8.98K
Volume8.98K
52 Week high
$26.19
52 Week high$26.19
52 Week low
$3.91
52 Week low$3.91

DBVT News

TipRanks 4d
DBV Technologies announces Phase 3 Vitesse trial met primary endpoint

DBV Technologies (DBVT) announced that the company shared additional positive data from the successful Phase 3 Vitesse clinical trial as an oral presentation at...

Analyst ratings

89%

of 9 ratings
Buy
88.9%
Hold
0%
Sell
11.1%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.